Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

BOTA 2.18 0.00 (0.00%)
price chart
What after Joseph Patti's Insider Purchase of Biota Pharmaceuticals Inc ...
Joseph Patti; that is an insider in Biota Pharmaceuticals Inc (NASDAQ:BOTA) 2.22 0.00 0.00% who is the latest to obtain shares in the firm for which he is the current CEO.
Biota Pharmaceuticals CEO Joseph M. Patti Buys 20000 Shares (BOTA)  Mideast Time
Biota Pharmaceuticals Inc Stock Downgraded (BOTA)
The gross profit margin for BIOTA PHARMACEUTICALS INC is currently lower than what is desirable, coming in at 34.92%. It has decreased significantly from the same period last year.
Related articles »  
Biota Pharmaceuticals to Host Conference Call to Report Third Quarter Fiscal ...
Biota Pharmaceuticals, Inc. BOTA, +4.07% a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that it will ...
Biota Pharmaceuticals to Acquire Anaconda Pharma
ATLANTA, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) (the "Company") announced today that it has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, ...
Biota to Acquire Anaconda Pharma for Up-to-$38M  Genetic Engineering & Biotechnology News
Biota Pharmaceuticals: Recent Progress Illustrates Buying Opportunity Remains ...
While the termination of the BARDA contract in April 2014 that provided up $231 million for the development of laninamivir octanoate had a substantial negative effect on Biota in 2014 as it took away a source of major funding, the company has made ...
Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals ...
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) is a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat a number of serious and potentially life-threatening infectious diseases.
Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics (NASDAQ: FOLD ) popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals (NASDAQ: BOTA ) collapsed ...
Related articles »  
Biota Pharmaceuticals: An Undervalued Long-Term Influenza Play (BOTA)
There is also $3.7 million of deferred revenue that Biota has not included as accrued revenue as the company is less certain of its collection.
Biota Pharmaceuticals relos HQ to Atlanta
A Northeast biopharmaceutical company is relocating its headquarters to Alpharetta as part of a consolidation and corporate restructuring.
Biota Pharmaceuticals to Make Alpharetta, GA Its New Home  GPB (blog)
Related articles »  
34% Drop in Biota Pharmaceutical, Inc.'s Stock Price: Law Firm Investigates on ...
Shares of Biota Pharmaceuticals fell 34%, to close at $3.68 on April 29, 2014, following an announcement by the company that the U.S. Department of Health and Human Services office of the Assistant Secretary for Preparedness and Response and ...
Related articles »